@inproceedings{inproceedings, title  = {{Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC.}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{http://dx.doi.org/10.1200/jco.2010.28.15_suppl.7516 }},

 year = {{2010}},

 month = {{5}},

 author = {{Johnson BE and Ryan AJ and Heymach J and Stephens C and Kennedy SJ and Langmuir PB and Herbst RS}},

 doi = {{10.1200/jco.2010.28.15_suppl.7516}},

 volume = {{28}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{15_suppl}},

 pages = {{7516-7516}},

 note = {{Accessed on 2024/10/23}}}